BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 36621872)

  • 1. Engineered nanomedicines for augmenting the efficacy of colorectal cancer immunotherapy.
    Abdelgalil RM; Elmorshedy YM; Elkhodairy KA; Teleb M; Bekhit AA; Khattab SN; Elzoghby AO
    Nanomedicine (Lond); 2022 Sep; 17(22):1721-1745. PubMed ID: 36621872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory nanomedicine for colorectal cancer treatment: a landscape to be explored?
    Silveira MJ; Castro F; Oliveira MJ; Sarmento B
    Biomater Sci; 2021 May; 9(9):3228-3243. PubMed ID: 33949441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-assembled traditional Chinese nanomedicine modulating tumor immunosuppressive microenvironment for colorectal cancer immunotherapy.
    Mao Q; Min J; Zeng R; Liu H; Li H; Zhang C; Zheng A; Lin J; Liu X; Wu M
    Theranostics; 2022; 12(14):6088-6105. PubMed ID: 36168633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor immune microenvironment and nano-immunotherapeutics in colorectal cancer.
    Xiong Y; Wang Y; Tiruthani K
    Nanomedicine; 2019 Oct; 21():102034. PubMed ID: 31207314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy.
    Ji B; Wei M; Yang B
    Theranostics; 2022; 12(1):434-458. PubMed ID: 34987658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment.
    Sun B; Hyun H; Li LT; Wang AZ
    Acta Pharmacol Sin; 2020 Jul; 41(7):970-985. PubMed ID: 32424240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-Microenvironment-Responsive Nanomedicine for Enhanced Cancer Immunotherapy.
    Peng S; Xiao F; Chen M; Gao H
    Adv Sci (Weinh); 2022 Jan; 9(1):e2103836. PubMed ID: 34796689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research advances in nanomedicine applied to the systemic treatment of colorectal cancer.
    Yin L; Li H; Shi L; Chen K; Pan H; Han W
    Int J Cancer; 2023 Mar; 152(5):807-821. PubMed ID: 35984398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remodeling tumor microenvironment with nanomedicines.
    Martin JD; Miyazaki T; Cabral H
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Nov; 13(6):e1730. PubMed ID: 34124849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicines for reversing immunosuppressive microenvironment of hepatocellular carcinoma.
    Pan X; Ni S; Hu K
    Biomaterials; 2024 Apr; 306():122481. PubMed ID: 38286109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy.
    Zhang R; Wan Y; Lv H; Li F; Lee CS
    J Mater Chem B; 2021 Sep; 9(36):7544-7556. PubMed ID: 34551052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy.
    Elzoghby AO; Ferrone CR; Ferrone S; Nasr ML
    Drug Discov Today; 2023 Jan; 28(1):103434. PubMed ID: 36368630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.
    Martin JD; Cabral H; Stylianopoulos T; Jain RK
    Nat Rev Clin Oncol; 2020 Apr; 17(4):251-266. PubMed ID: 32034288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle-Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions.
    Liu J; Zhang R; Xu ZP
    Small; 2019 Aug; 15(32):e1900262. PubMed ID: 30908864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy.
    Li W; Peng A; Wu H; Quan Y; Li Y; Lu L; Cui M
    Front Immunol; 2020; 11():601497. PubMed ID: 33408716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanomedicine Strategies for Heating "Cold" Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC.
    Yang Y; Zhao T; Chen Q; Li Y; Xiao Z; Xiang Y; Wang B; Qiu Y; Tu S; Jiang Y; Nan Y; Huang Q; Ai K
    Adv Sci (Weinh); 2022 Oct; 9(28):e2202797. PubMed ID: 35869032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticle mediated cancer immunotherapy.
    Gupta J; Safdari HA; Hoque M
    Semin Cancer Biol; 2021 Feb; 69():307-324. PubMed ID: 32259643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Abnormality-Oriented Nanomedicine Design.
    Zhou Q; Xiang J; Qiu N; Wang Y; Piao Y; Shao S; Tang J; Zhou Z; Shen Y
    Chem Rev; 2023 Sep; 123(18):10920-10989. PubMed ID: 37713432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.